Atara Biotherapeutics (ATRA) Invested Capital (2022 - 2025)
Atara Biotherapeutics (ATRA) has disclosed Invested Capital for 4 consecutive years, with -$36.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Invested Capital rose 59.54% year-over-year to -$36.6 million, compared with a TTM value of -$36.6 million through Sep 2025, up 59.54%, and an annual FY2024 reading of -$97.3 million, up 1.96% over the prior year.
- Invested Capital was -$36.6 million for Q3 2025 at Atara Biotherapeutics, down from -$35.0 million in the prior quarter.
- Across five years, Invested Capital topped out at $257.5 million in Q2 2022 and bottomed at -$110.9 million in Q2 2024.
- Average Invested Capital over 4 years is $12.9 million, with a median of -$36.6 million recorded in 2025.
- The sharpest move saw Invested Capital tumbled 1587.36% in 2024, then soared 68.39% in 2025.
- Year by year, Invested Capital stood at $126.6 million in 2022, then tumbled by 178.36% to -$99.2 million in 2023, then grew by 1.96% to -$97.3 million in 2024, then surged by 62.34% to -$36.6 million in 2025.
- Business Quant data shows Invested Capital for ATRA at -$36.6 million in Q3 2025, -$35.0 million in Q2 2025, and -$55.1 million in Q1 2025.